(GERN) Geron - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US3741631036

Stock: Cancer Drugs, Therapeutics

Total Rating 23

Risk 78

Buy Signal -1.06

Biotechnology +4.9
Biotechnology +3.0

Market Cap: 1,072m
Avg Trading Vol: 26.4M USD

ATR: 9.66%
Peers RS (IBD): 20.3

Risk 5d forecast
Volatility	68.9%
Relative Tail Risk	-9.47%

Reward TTM
Sharpe Ratio	0.02
Alpha	-39.80

Character TTM
Beta	1.380
Beta Downside	1.104

Drawdowns 3y
Max DD	78.98%
CAGR/Max DD	-0.26

EPS (Earnings per Share)

EPS CAGR: 53.04%
EPS Trend: 79.2%

Last SUE: 0.54
Qual. Beats: 0

Revenue

Rev. CAGR: 390.97%
Rev. Trend: 84.3%

Last SUE: -0.44
Qual. Beats: 0

Description: GERN Geron March 05, 2026

Geron Corporation (NASDAQ: GERN) is a commercial-stage biopharmaceutical company specializing in oncology therapeutics.

Their primary product is RYTELO, a telomerase inhibitor. This drug treats myelodysplastic syndromes (MDS) in adult patients who have low- to intermediate-1 risk and transfusion-dependent anemia. MDS is a group of cancers where immature blood cells in the bone marrow do not mature or become healthy blood cells.

The company, founded in 1990, operates from Foster City, California. The biotechnology sector is characterized by extensive research and development cycles and significant regulatory hurdles for product approval.

For more in-depth analysis of Gerons financials and market position, consider exploring ValueRay.

Piotroski VR‑10 (Strict, 0-10) 1.5

Net Income: -85.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.23 > 0.02 and ΔFCF/TA 13.18 > 1.0
NWC/Revenue: 221.0% < 20% (prev 523.0%; Δ -302.0% < -1%)
CFO/TA -0.23 > 3% & CFO -132.9m > Net Income -85.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 4.57 > 1.5 & < 3
Outstanding Shares: last quarter (667.2m) vs 12m ago 3.27% < -2%
Gross Margin: 85.96% > 18% (prev 0.98%; Δ 8498 % > 0.5%)
Asset Turnover: 31.59% > 50% (prev 12.97%; Δ 18.62% > 0%)
Interest Coverage Ratio: -0.90 > 6 (EBITDA TTM -39.3m / Interest Expense TTM 32.7m)

Altman Z'' -5.43

A: 0.71 (Total Current Assets 520.3m - Total Current Liabilities 113.8m) / Total Assets 570.5m
B: -3.20 (Retained Earnings -1.83b / Total Assets 570.5m)
C: -0.05 (EBIT TTM -29.3m / Avg Total Assets 582.2m)
D: 0.64 (Book Value of Equity 223.6m / Total Liabilities 346.9m)
Altman-Z'' Score: -5.43 = D

Beneish M

DSRI: none (Receivables none/38.8m, Revenue 183.9m/77.0m)
GMI: 1.14 (GM 85.96% / 98.01%)
AQI: 0.52 (AQ_t 0.09 / AQ_t-1 0.17)
SGI: 2.39 (Revenue 183.9m / 77.0m)
TATA: 0.08 (NI -85.8m - CFO -132.9m) / TA 570.5m)
Beneish M-Score: cannot calculate (missing components)

What is the price of GERN shares?

As of March 06, 2026, the stock is trading at USD 1.42 with a total of 17,836,138 shares traded.
Over the past week, the price has changed by -13.94%, over one month by -2.74%, over three months by +8.40% and over the past year by -15.48%.

Is GERN a buy, sell or hold?

Geron has received a consensus analysts rating of 4.11. Therefore, it is recommended to buy GERN.

StrongBuy: 4
Buy: 2
Hold: 3
Sell: 0
StrongSell: 0

What are the forecasts/targets for the GERN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	3.4	139.4%
Analysts Target Price	3.4	139.4%

GERN Fundamental Data Overview March 02, 2026

P/S = 5.8322
P/B = 4.312
P/EG = -2.38
Revenue TTM = 183.9m USD
EBIT TTM = -29.3m USD
EBITDA TTM = -39.3m USD
Long Term Debt = 119.3m USD (from longTermDebt, two quarters ago)
Short Term Debt = 994.0k USD (from shortTermDebt, two quarters ago)
Debt = 121.9m USD (from shortLongTermDebtTotal, two quarters ago)
Net Debt = -79.4m USD (from netDebt column, last quarter)
Enterprise Value = 834.6m USD (1.07b + Debt 121.9m - CCE 359.8m)
Interest Coverage Ratio = -0.90 (Ebit TTM -29.3m / Interest Expense TTM 32.7m)
EV/FCF = -6.28x (Enterprise Value 834.6m / FCF TTM -132.8m)
FCF Yield = -15.92% (FCF TTM -132.8m / Enterprise Value 834.6m)
FCF Margin = -72.23% (FCF TTM -132.8m / Revenue TTM 183.9m)
Net Margin = -46.65% (Net Income TTM -85.8m / Revenue TTM 183.9m)
Gross Margin = 85.96% ((Revenue TTM 183.9m - Cost of Revenue TTM 25.8m) / Revenue TTM)
Gross Margin QoQ = none% (prev 53.18%)
Tobins Q-Ratio = 1.46 (Enterprise Value 834.6m / Total Assets 570.5m)
Interest Expense / Debt = 5.99% (Interest Expense 7.30m / Debt 121.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -23.1m (EBIT -29.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.57 (Total Current Assets 520.3m / Total Current Liabilities 113.8m)
Debt / Equity = 0.55 (Debt 121.9m / totalStockholderEquity, last quarter 223.6m)
Debt / EBITDA = 2.02 (negative EBITDA) (Net Debt -79.4m / EBITDA -39.3m)
Debt / FCF = 0.60 (negative FCF - burning cash) (Net Debt -79.4m / FCF TTM -132.8m)
Total Stockholder Equity = 250.0m (last 4 quarters mean from totalStockholderEquity)
RoA = -14.74% (Net Income -85.8m / Total Assets 570.5m)
RoE = -34.31% (Net Income TTM -85.8m / Total Stockholder Equity 250.0m)
RoCE = -7.93% (EBIT -29.3m / Capital Employed (Equity 250.0m + L.T.Debt 119.3m))
RoIC = -6.12% (negative operating profit) (NOPAT -23.1m / Invested Capital 377.8m)
WACC = 10.36% (E(1.07b)/V(1.19b) * Re(11.0%) + D(121.9m)/V(1.19b) * Rd(5.99%) * (1-Tc(0.21)))
Discount Rate = 11.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 5.89%
[DCF] Fair Price = unknown (Cash Flow -132.8m)
EPS Correlation: 79.18 | EPS CAGR: 53.04% | SUE: 0.54 | # QB: 0
Revenue Correlation: 84.34 | Revenue CAGR: 391.0% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.01 | Chg7d=-0.005 | Chg30d=-0.005 | Revisions Net=+1 | Analysts=1
EPS current Year (2026-12-31): EPS=-0.02 | Chg7d=+0.005 | Chg30d=+0.005 | Revisions Net=+0 | Growth EPS=+80.6% | Growth Revenue=+24.7%
EPS next Year (2027-12-31): EPS=0.08 | Chg7d=-0.015 | Chg30d=-0.015 | Revisions Net=+1 | Growth EPS=+500.0% | Growth Revenue=+44.1%

Additional Sources for GERN Stock

Fund Manager Positions: Dataroma | Stockcircle